Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
NEUROLOGIX INC (NRGX) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/22/2012 8-K Quarterly results
03/21/2012 8-K Form 8-K - Current report
02/16/2012 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Limited Engagement Agreement, entered into by the Company on February 14, 2012, by and between the Company and Global Resource Partners, Inc"
02/14/2012 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/27/2012 8-K Form 8-K - Current report
12/21/2011 8-K Form 8-K - Current report
11/30/2011 8-K Form 8-K - Current report
10/31/2011 8-K Form 8-K - Current report
10/18/2011 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
Docs: "Certificate of Amendment of Restated Certificate of Incorporation of Neurologix, Inc., filed with the Secretary of State of the State of Delaware on October 14, 2011"
09/27/2011 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Letter Agreement dated September 26, 2011, by and between Neurologix, Inc. and Dr. Matthew J. During"
09/20/2011 8-K Unregistered Sales of Equity Securities, Departure of Directors or Certain Officers; Election of Directors; Appointment of Ce...
Docs: "Amendment to Amended and Restated By-Laws of Neurologix, Inc., effective September 19, 2011",
"Executive Employment Agreement between Adrian Adams and Neurologix, Inc.",
"Executive Employment Agreement between Andrew I. Koven and Neurologix, Inc.",
"Stand-Alone Stock Option Agreement between Adrian Adams and Neurologix, Inc.",
"Stand-Alone Stock Option Agreement between Andrew I. Koven and Neurologix, Inc.",
"Press release of Neurologix, Inc."
08/11/2011 8-K Quarterly results
Docs: "NEUROLOGIX, INC. BALANCE SHEETS June 30, 2011 December 31, 2010 ASSETS Current assets: Cash and cash equivalents $ 3,453 $ 8,055 Prepaid expenses and other current assets 319 481 Total current assets 3,772 8,536 Equipment, less accumulated depreciation of $704 and $682 at June 30, 2011 and December 31, 2010, respectively 49 71 Intangible assets, less accumulated amortization of $426 and $364 at June 30, 2011 and December 31, 2010, respectively 1,137 1,065 Other assets 5 5 Total assets $ 4,963 $ 9,677 LIABILITIES AND STOCKHOLDERS’ DEFICIT Current liabilities: Accounts payable and accrued expenses $ 3,375 $ 2,302 Notes payable, net of discount 6,078 4,695 Total current liabilities 9,453 6,997 Derivative financial instruments, at estimated fair value – warrants 4,174 6,840 Total liabilities $..."
08/04/2011 8-K Form 8-K - Current report
06/08/2011 8-K Form 8-K - Current report
05/26/2011 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Slides related to one-year efficacy results of Neurologix, Inc’s Phase 2 trial for Parkinson’s disease (furnished pursuant to Item 7.01 of Form 8-K)",
"NEUROLOGIX PRESENTS ONE-YEAR FOLLOW-UP DATA FROM PHASE 2 STUDY OF NLX-P101 IN PARKINSON’S DISEASE AT INTERNATIONAL NEUROMODULATION SOCIETY 10th WORLD CONGRESS"
05/13/2011 8-K Submission of Matters to a Vote of Security Holders
05/13/2011 8-K Quarterly results
Docs: "Neurologix Announces First Quarter 2011 Financial Results Fort Lee, New Jersey ? Neurologix, Inc. , a biotechnology company engaged in the development of innovative gene therapies for disorders of the brain and central nervous system, today announced its financial results for the three months ended March 31, 2011."
05/02/2011 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Letter Agreement between Neurologix, Inc. and Dr. Michael G. Kaplitt. 2"
03/25/2011 8-K Form 8-K - Current report
02/11/2011 8-K Form 8-K - Current report
01/20/2011 8-K Form 8-K - Current report
12/06/2010 8-K Form 8-K - Current report
11/30/2010 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Letter Agreement between Marc L. Panoff and Neurologix, Inc."
10/01/2010 8-K Form 8-K - Current report
08/12/2010 8-K Form 8-K - Current report
06/22/2010 8-K Other Events, Financial Statements and Exhibits
Docs: "NEUROLOGIX ANNOUNCES SUCCESSFUL PHASE 2 TRIAL OF GENE THERAPY FOR PARKINSON'S DISEASE"
05/14/2010 8-K Submission of Matters to a Vote of Security Holders
05/13/2010 8-K Quarterly results
Docs: "Neurologix Announces Q1 2010 Financial Results"
03/26/2010 8-K Form 8-K - Current report
03/11/2010 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Clark Johnson Appointed Neurologix President and CEO FORT LEE, N.J., - Neurologix, Inc. , a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, today announced that Clark A. Johnson, the Vice Chairman of Neurologix , has been appointed as the Company's President and Chief Executive Officer to replace John E. Mordock, who resigned. Mr. Johnson was a founder of the Company and has served on its Board of Directors since the Company's inception. Mr. Johnson was Chairman of PSS World Medical, Inc. from 2000 to 2007, during that period of its greatest growth in sales and income. He retired as Chairman and Chief Executive Officer of Pier I Imports in 1998 after 13 years heading that company. Neurologix recently announced completion of..."
02/22/2010 8-K Form 8-K - Current report
11/25/2009 8-K Form 8-K - Current report
11/12/2009 8-K Quarterly results
Docs: "Cautionary Statement Regarding Forward-looking Statements"
09/24/2009 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Third Amendment to Master Sponsored Research Agreement between Neurologix, Inc. and The Ohio State University Research Foundation, on behalf of Ohio State University"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy